- Home
- ARQT vs DAVE Comparison
ARQT vs DAVE Comparison
Compare ARQT & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DAVE
- Stock Information
- Founded
- ARQT 2016
- DAVE 2017
- Country
- ARQT United States
- DAVE United States
- Employees
- ARQT N/A
- DAVE N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DAVE Retail: Computer Software & Peripheral Equipment
- Sector
- ARQT Health Care
- DAVE Technology
- Exchange
- ARQT Nasdaq
- DAVE Nasdaq
- Market Cap
- ARQT 1.7B
- DAVE 2.9B
- IPO Year
- ARQT 2020
- DAVE N/A
- Fundamental
- Price
- ARQT $13.78
- DAVE $282.00
- Analyst Decision
- ARQT Strong Buy
- DAVE Strong Buy
- Analyst Count
- ARQT 6
- DAVE 6
- Target Price
- ARQT $18.80
- DAVE $227.50
- AVG Volume (30 Days)
- ARQT 2.0M
- DAVE 482.8K
- Earning Date
- ARQT 08-13-2025
- DAVE 08-04-2025
- Dividend Yield
- ARQT N/A
- DAVE N/A
- EPS Growth
- ARQT N/A
- DAVE N/A
- EPS
- ARQT N/A
- DAVE 3.70
- Revenue
- ARQT $212,819,000.00
- DAVE $381,425,000.00
- Revenue This Year
- ARQT $61.15
- DAVE $37.77
- Revenue Next Year
- ARQT $37.98
- DAVE $17.77
- P/E Ratio
- ARQT N/A
- DAVE $76.16
- Revenue Growth
- ARQT 100.03
- DAVE 39.31
- 52 Week Low
- ARQT $7.86
- DAVE $28.74
- 52 Week High
- ARQT $17.75
- DAVE $282.99
- Technical
- Relative Strength Index (RSI)
- ARQT 46.51
- DAVE 74.48
- Support Level
- ARQT $13.51
- DAVE $252.01
- Resistance Level
- ARQT $14.31
- DAVE $280.31
- Average True Range (ATR)
- ARQT 0.61
- DAVE 17.10
- MACD
- ARQT -0.01
- DAVE 3.57
- Stochastic Oscillator
- ARQT 46.95
- DAVE 98.76
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.